Efficacy and safety of purslane (Portulaca oleracea) for mild to moderate chronic hand eczema; A randomized, double-blind, placebo-controlled clinical trial

• Published in: Explore (New York, N.Y.) Vol. 20; no. 3; pp. 401 - 410
• Main Authors: Heydarirad, Ghazaleh, Rastegar, Sedigheh, Haji-Abdolvahab, Habibbolah, Fuzimoto, Andréa, Hunter, Jennifer, Zare, Roghayeh, Pasalar, Mehdi
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2024
• Subjects: Adult; Chronic Disease; Chronic hand eczema; Double-Blind Method; Eczema - drug therapy; Female; Hand dermatitis; Hand Dermatoses - drug therapy; Humans; Iran; Male; Middle Aged; Persian medicine; Phytotherapy - methods; Plant Extracts - therapeutic use; Portulaca; Portulaca oleracea; Purslane; Quality of Life; Severity of Illness Index; Skin; Treatment Outcome; Iran; Chronic hand eczema; Skin; Hand dermatitis; Purslane; Persian medicine; Portulaca oleracea
• ISSN: 1550-8307; 1878-7541
• DOI: 10.1016/j.explore.2023.10.005

•Purslane extract showed promising results in treating chronic hand eczema (CHE) symptoms.•Purslane syrup improved fissure, itching, dryness, and patient's self-reporting of symptoms in patients with CHE, significantly.•Purslane syrup was well-tolerated and associated with higher treatment satisfaction.•Future studies could establish the safety and effectiveness of purslane as a potential therapeutic agent for CHE. Chronic hand eczema (CHE) is a common skin inflammation with a complex pathophysiology. Due to its anti-inflammatory properties, Portulaca oleracea L. (purslane) is traditionally used in Persian medicine for skin ailments. This study aimed to evaluate the safety and efficacy of a standardized purslane extract (based on traditional Persian medicine) for adults with mild or moderately severe CHE. A randomized, double-blind, placebo-controlled clinical trial was conducted at Razi Hospital in Iran from January to June 2022. Participants were randomly allocated to receive an oral purslane or placebo syrup plus topical Vaseline for four weeks. Seventy participants were randomly allocated into the intervention (n = 35) and placebo (n = 35) groups. The primary outcomes were the extent and severity of CHE symptoms over the four weeks after adjusting for age, gender and baseline score. Secondary outcomes were quality of life, symptom recurrence, treatment satisfaction, and adverse events. After 4 weeks of treatment, compared to the placebo group (n = 31), the purslane group (n = 31) had significantly lower physician-reported fissure scores (adjusted mean difference (adjMD): -0.50, 95 %CI -3.93 to -0.34, p = 0.043), participant-reported itching (adjMD -0.51, 95 %CI -2.32 to -0.31, p = 0.041), dryness (adjMD -1.46, 95 %CI -2.89 to -0.03, p = 0.045), and total itching, dryness and thickness (adjMD -2.36, 95 %CI -6.23 to -1.51, p = 0.023) scores. Fourteen participants (purslane n = 10; placebo n = 4, p = 0.068) experienced adverse events of mild to moderate severity. Purslane has some promising effects for reducing the extent and severity of CHE symptoms, and no direct comparisons have been made with commonly used treatments. Future multicenter trials and mechanistic studies are warranted to establish the safety and effectiveness of purslane as a potential therapeutic agent for CHE. Iranian Registry of Clinical Trials (IRCT20200707048040N1).